Comparative Pharmacology
Head-to-head clinical analysis: MINIZIDE versus NORMOZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINIZIDE versus NORMOZIDE.
MINIZIDE vs NORMOZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
None Documented
None Documented
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination